Rasekh HR, Imani A, Karimi M, & Golestani M. (2011). Cost-utility analysis of immune tolerance induction therapy versus on-demand treatment with recombinant factor VII for hemophilia A with high titer inhibitors in Iran. Dove Medical Press.
Chicago Style (17th ed.) CitationRasekh HR, Imani A, Karimi M, and Golestani M. Cost-utility Analysis of Immune Tolerance Induction Therapy Versus On-demand Treatment with Recombinant Factor VII for Hemophilia A with High Titer Inhibitors in Iran. Dove Medical Press, 2011.
MLA (9th ed.) CitationRasekh HR, et al. Cost-utility Analysis of Immune Tolerance Induction Therapy Versus On-demand Treatment with Recombinant Factor VII for Hemophilia A with High Titer Inhibitors in Iran. Dove Medical Press, 2011.
Warning: These citations may not always be 100% accurate.